Revvomed

1. 31 Oct 2026

   Funding round

   €638K

   Cumulative €638K

Amounts in EUR, converted at the ECB rate on the event date. Funding totals exclude debt, grants and state aid; rounds whose instrument is not yet established are still counted. Every figure links to its source.

• Funding31 Oct 2026EUR 638K

  Revvomed has raised 7 million Swedish kronor to fund its development of new cancer drug candidates.

  ▸Source: Breakit

  “Revvomed vill kartlägga membranproteiner för att hitta nya angreppspunkter mot cancer. Nu får bolaget in sina första miljoner i kapital – bland annat från serieentreprenören Johan Staël von Holstein.”

  Read at Breakit

• Erik Wikström

• Johan Staël von Holstein

• Nina Schiller

  CEO & Co-founder

What does Revvomed do?

Revvomed is engaged in pharmaceutical research, aiming to develop new cancer drug candidates.

Where is Revvomed headquartered?

Revvomed is based in Sweden.

How much funding has Revvomed raised?

Revvomed has raised €638K (across 1 round · last 31 Oct 2026).

What was Revvomed's latest funding round?

Revvomed's most recent disclosed round was a funding round of €638K, announced 31 October 2026.

Who has invested in Revvomed?

Investors in Revvomed include Erik Wikström, Johan Staël von Holstein.